Long-Term Debt (Details) - USD ($)	1 Months Ended		12 Months Ended
	Nov. 30, 2018	Nov. 30, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Long-Term Debt
Total long-term debt			$ 454,353,000	$ 223,746,000
Long-term debt interest expense
Stated coupon interest			9,316,000	7,475,000	$ 1,225,000
Amortization of Debt Issuance Costs			1,166,000	1,072,000	179,000
Total long-term debt interest expense			$ 10,482,000	8,547,000	$ 1,404,000
Equity interest			85.00%
3.25% Convertible Senior Notes Due 2023
Long-Term Debt
Principal amount			$ 230,000,000	230,000,000
Unamortized debt issuance costs			$ (5,182,000)	$ (6,254,000)
Long-term debt interest expense
Proceeds from issuance of debt		$ 222,500,000
Interest rate (as a percent)		3.25%	3.25%	3.25%
Transaction costs		$ 7,500,000
Conversion rate, in shares			29.0276
Principal amount for conversion rate			$ 1,000
Conversion price (in dollars per share)			$ 34.45
Redemption price to principal amount, in percent			100.00%
3.25% Convertible Senior Notes Due 2023 | Level 2
Long-term debt interest expense
Notes fair value			$ 235,000,000	$ 251,000,000
9.0% non-recourse notes due 2033
Long-Term Debt
Principal amount			237,500,000
Unamortized debt issuance costs			$ (7,965,000)
Long-term debt interest expense
Proceeds from issuance of debt	$ 250,000,000
Interest rate (as a percent)	9.00%		9.00%	9.00%
Non-recourse of debt	$ 12,500,000
Net proceeds	229,400,000
Transaction costs	$ 8,100,000
Equity interest	63.75%
9.0% non-recourse notes due 2033 | Level 2
Long-term debt interest expense
Notes fair value			$ 237,500,000
TRC
Long-term debt interest expense
Equity interest			85.00%
Theravance Biopharma R&D, Inc. | 9.0% non-recourse notes due 2033
Long-term debt interest expense
Interest rate (as a percent)	5.00%